A new trading day began on Monday, with Exagen Inc (NASDAQ: XGN) stock price down -6.15% from the previous day of trading, before settling in for the closing price of $6.34. XGN’s price has ranged from $2.67 to $12.23 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 19.20% over the past five years. Meanwhile, its annual earnings per share averaged -6.33%. With a float of $15.32 million, this company’s outstanding shares have now reached $22.51 million.
Exagen Inc (XGN) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Diagnostics & Research Industry. The insider ownership of Exagen Inc is 32.38%, while institutional ownership is 43.86%. The most recent insider transaction that took place on Oct 16 ’25, was worth 375,598. In this transaction President and CEO of this company sold 31,787 shares at a rate of $11.82, taking the stock ownership to the 714,427 shares. Before that another transaction happened on Sep 02 ’25, when Company’s Chief Financial Officer sold 20,466 for $9.79, making the entire transaction worth $200,362. This insider now owns 269,026 shares in total.
Exagen Inc (XGN) Performance Highlights and Predictions
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.2 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -6.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 35.78% during the next five years compared to 19.20% growth over the previous five years of trading.
Exagen Inc (NASDAQ: XGN) Trading Performance Indicators
Here are Exagen Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.12.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.93, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -0.47 in one year’s time.
